Experienced in Relapsed Refractory Multiple Myeloma (RRMM)

Dr. Juan C. Varela

Hematology | Oncology
Orlando Health Medical Group Inc
1400 S Orange Ave, 
Orlando, FL 
Clinical Trials:Currently Recruiting for 3 Trials
Accepting New Patients
Offers Telehealth
19 Years of Experience
Experienced in Relapsed Refractory Multiple Myeloma (RRMM)
Orlando Health Medical Group Inc
1400 S Orange Ave, 
Orlando, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Juan Varela is a Hematologist and an Oncologist in Orlando, Florida. Dr. Varela has been practicing medicine for over 19 years and is rated as an Experienced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Varela is currently accepting new patients.

His clinical research consists of co-authoring 29 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Relapsed Refractory Multiple Myeloma (RRMM).

Specialties
Hematology
Oncology
Hospital Affiliations
Orlando Health
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

ORLANDO HEALTH MEDICAL GROUP INC
1400 S Orange Ave, Orlando, FL 32806
Other Locations
ORLANDO HEALTH MEDICAL GROUP INC
32 W Gore St, Orlando, FL 32806

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: April 17, 2025
Intervention Type: Drug
A Phase 1, Open-Label, Dose-Escalation with Expansion Study of SX-682 Alone and in Combination with Oral or Intravenous Decitabine in Subjects with Myelodysplastic Syndrome
A Phase 1, Open-Label, Dose-Escalation with Expansion Study of SX-682 Alone and in Combination with Oral or Intravenous Decitabine in Subjects with Myelodysplastic Syndrome
Enrollment Status: Recruiting
Publish Date: November 25, 2024
Intervention Type: Drug
Study Drug: SX-682 CXCR1/CXCR2 Small Molecule Inhibitor
Study Phase: Phase 1
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Enrollment Status: Recruiting
Publish Date: April 19, 2024
Intervention Type: Biological
Study Phase: Phase 2
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: September 30, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting
Enrollment Status: Completed
Publish Date: February 27, 2025
Intervention Type: Biological
Study Drug: lisocabtagene maraleucel
Study Phase: Phase 2
A Phase I/II Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias or Myelodysplastic Syndromes
A Phase I/II Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias or Myelodysplastic Syndromes
Enrollment Status: Terminated
Publish Date: July 15, 2024
Intervention Type: Drug
Study Drugs: ONO-7475, Venetoclax
Study Phase: Phase 1/Phase 2
A Phase 1 / 2 Study to Evaluate the Safety and Tolerability of Adoptively Transferred Autologous T Cells in Patients With Relapsed Refractory Multiple Myeloma
A Phase 1 / 2 Study to Evaluate the Safety and Tolerability of Adoptively Transferred Autologous T Cells in Patients With Relapsed Refractory Multiple Myeloma
Enrollment Status: Suspended
Publish Date: January 16, 2024
Intervention Type: Biological
Study Drug: NEXI-002 T Cells
Study Phase: Phase 1/Phase 2
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2024
Intervention Type: Biological
Study Drug: NEXI-001 T Cell Infusion
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

29 Total Publications

OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL.
OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL.
Journal: Blood advances
Published: March 25, 2024
Similar Doctors
Experienced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Yasser A. Khaled
Oncology | Hematology
Experienced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Yasser A. Khaled
Oncology | Hematology

Orlando Health Medical Group Inc

1400 S Orange Ave, 
Orlando, FL 
 (0.1 miles away)
321-841-6600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Yasser Khaled is an Oncologist and a Hematologist in Orlando, Florida. Dr. Khaled is rated as an Advanced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Multiple Myeloma, Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Khaled is currently accepting new patients.

Advanced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Jose E. Sarriera
Hematology Oncology | Hematology | Oncology
Advanced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Jose E. Sarriera
Hematology Oncology | Hematology | Oncology

Orlando Health Medical Group Inc

1400 S Orange Ave, 
Orlando, FL 
 (0.1 miles away)
321-841-6600
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jose Sarriera is a Hematologist Oncology specialist and a Hematologist in Orlando, Florida. Dr. Sarriera is rated as a Distinguished provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma, Chronic B-Cell Leukemia (CBCL), and Bone Marrow Aspiration. Dr. Sarriera is currently accepting new patients.

Experienced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Mickey Liao
Hematology Oncology | Hematology | Oncology
Experienced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Mickey Liao
Hematology Oncology | Hematology | Oncology

Orlando Health Medical Group Inc

1400 S Orange Ave, 
Orlando, FL 
 (0.1 miles away)
321-841-6600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mickey Liao is a Hematologist Oncology specialist and a Hematologist in Orlando, Florida. Dr. Liao is rated as a Distinguished provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma, Familial Colorectal Cancer, and Colorectal Cancer. Dr. Liao is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Varela's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 24 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile